212 related articles for article (PubMed ID: 27744089)
1. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial.
Gandhi PU; Gaggin HK; Redfield MM; Chen HH; Stevens SR; Anstrom KJ; Semigran MJ; Liu P; Januzzi JL
JACC Heart Fail; 2016 Nov; 4(11):860-869. PubMed ID: 27744089
[TBL] [Abstract][Full Text] [Related]
2. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function?
Gandhi PU; Gaggin HK; Sheftel AD; Belcher AM; Weiner RB; Baggish AL; Motiwala SR; Liu PP; Januzzi JL
Am J Cardiol; 2014 Nov; 114(10):1543-9. PubMed ID: 25248814
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
[TBL] [Abstract][Full Text] [Related]
4. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD
Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399
[TBL] [Abstract][Full Text] [Related]
5. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
Jacobshagen C; Belardinelli L; Hasenfuss G; Maier LS
Clin Cardiol; 2011 Jul; 34(7):426-32. PubMed ID: 21538388
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
[TBL] [Abstract][Full Text] [Related]
8. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme.
Ferreira JP; Packer M; Sattar N; Butler J; González Maldonado S; Panova-Noeva M; Sumin M; Masson S; Pocock SJ; Anker SD; Zannad F; Januzzi JL
Eur J Heart Fail; 2024 Apr; 26(4):806-816. PubMed ID: 38587259
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM
J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521
[TBL] [Abstract][Full Text] [Related]
12. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
13. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
[TBL] [Abstract][Full Text] [Related]
15. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
[TBL] [Abstract][Full Text] [Related]
16. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial.
Wang H; Anstrom K; Ilkayeva O; Muehlbauer MJ; Bain JR; McNulty S; Newgard CB; Kraus WE; Hernandez A; Felker GM; Redfield M; Shah SH
JAMA Cardiol; 2017 Aug; 2(8):896-901. PubMed ID: 28492915
[TBL] [Abstract][Full Text] [Related]
18. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study.
Reddy YNV; Lewis GD; Shah SJ; Obokata M; Abou-Ezzedine OF; Fudim M; Sun JL; Chakraborty H; McNulty S; LeWinter MM; Mann DL; Stevenson LW; Redfield MM; Borlaug BA
Mayo Clin Proc; 2019 Jul; 94(7):1199-1209. PubMed ID: 31272568
[TBL] [Abstract][Full Text] [Related]
20. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
